Alzheimer's disease (AD) is one of the major health problems in this country and affects over 4.5 million persons. The key to the disease is understanding the pathogenesis of neuron degeneration in specific brain regions so that treatment and prevention can be based on solid data. This application is a resubmission of a competitive renewal of the program project, "Beta-Amyloid and Oxidative Stress in AD" (P01 AG05119-20) by the Sanders-Brown Center on Aging at the University of Kentucky (UK). Abundant evidence indicates that free radical mediated oxidative damage in the brain is prominent in AD, especially in the earliest detectable clinical phase of AD - mild cognitive impairment (MCI). The major hypothesis of this application is that beta amyloid peptide (AB) is one of the pivotal mechanisms in oxidative stress/damage to neurons in AD. The proposal consists of three cores including 1) an Administrative Core that provides supervision, fiscal management, biostatistical support and database management, clinical and neuropathological data, and brain specimens from the UK AD Center, 2) a unique Beta-Amyloid Core that will provide the AB index (total AB{1-40} and AB{1-42}, AB solubility, oligomeric and fibrillar AB quantitation and plaque quantitation) from human subjects and transgenic mice and also will provide toxic assembled AB and non-toxic scrambled AB for cell culture experiments, and 3) an Animal Core that will supply APP/PS1 knock-in mutant mice and WT mice, and primary rodent cortical neuron cultures for projects. Each project uses short postmortem brain specimens from longitudinally followed preclinical AD (PCAD), MCI, late AD, normal controls and frontotemporal dementia (as a disease control) subjects, APP/PS1 transgenic mice and cell cultures, and each has a therapeutic component and excellent preliminary data to support their hypotheses. Project 1 examines the hypothesis that brain RNA oxidation is an early event in AD and is mediated, at least in part, by Ap and that the RNA oxidation impairs protein synthesis and contributes to neuron dysfunction. Project 2 examines the hypothesis that AB-mediated oxidative modifications of and subsequent dysfunction of Pin1 are fundamental to the genesis of specific pathological features in AD. Project 3 will examine the hypothesis that elevations in RAGE-ligand interactions occur in AD, with soluble RAGE modulating Ap assembly and toxicity. Project 4 examines the hypothesis that sustained activation of NADPH oxidase by toxic forms of AB triggers a cascade linking increased ROS to altered redox-based signaling and neurotoxic oxidative damage. This well integrated program project will move the field of AB and oxidative stress in AD forward and gain insights into mechanisms of neuron degeneration so that successful interventions can be developed to treat or prevent the most dehumanizing disorder to affect humans.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG005119-24
Application #
8241979
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (O4))
Program Officer
Refolo, Lorenzo
Project Start
1997-05-15
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2014-03-31
Support Year
24
Fiscal Year
2012
Total Cost
$1,821,007
Indirect Cost
$448,256
Name
University of Kentucky
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Hartz, Anika M S; Zhong, Yu; Wolf, Andrea et al. (2016) Aβ40 Reduces P-Glycoprotein at the Blood-Brain Barrier through the Ubiquitin-Proteasome Pathway. J Neurosci 36:1930-41
Ellison, Elizabeth M; Abner, Erin L; Lovell, Mark A (2016) Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease. J Neurochem :
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Lovell, Mark A; Abner, Erin; Kryscio, Richard et al. (2015) Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. Oxid Med Cell Longev 2015:787805
Sethi, M; Joshi, S S; Webb, R L et al. (2015) Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's disease. Neuroscience 290:80-9
Barone, Eugenio; Cenini, Giovanna; Di Domenico, Fabio et al. (2015) Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. J Neurosci Res 93:1728-39
Chen, Chun-Hau; Li, Wenzong; Sultana, Rukhsana et al. (2015) Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol Dis 76:13-23
Bradley-Whitman, Melissa A; Lovell, Mark A (2015) Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol 89:1035-44
Di Domenico, Fabio; Pupo, Gilda; Mancuso, Cesare et al. (2015) Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease. J Alzheimers Dis 44:1107-20
Perluigi, Marzia; Pupo, Gilda; Tramutola, Antonella et al. (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta 1842:1144-53

Showing the most recent 10 out of 238 publications